Table 3. HR of progression and survival for patients treated with chemoradiation with concurrent CAPE or GEM with or without resectable patients in analysis.

Outcome	Borderline resectable and resectable			Borderline resectable only
	HR (95% CI)	AHR (95% CI)		HR (95% CI)	AHR (95% CI)
Progression	0.33 (0.14–0.81)	0.24 (0.07–0.80)		0.38 (0.15–0.96)	0.24 (0.08–0.77)
Survival	0.13 (0.04–0.40)	0.12 (0.03–0.49)		0.16 (0.05–0.49)	0.13 (0.03–0.52)

Gemcitabine was referent in all models. AHR is adjusted by year of diagnosis, weeks of neoadjuvant chemotherapy, and type of neoadjuvant chemotherapy. HR, hazard ratio; CAPE, capecitabine; GEM, gemcitabine; AHR, adjusted hazard ratio; CI, confidence interval.